49 results on '"Fumery M"'
Search Results
2. P927 Long-term outcomes of risankizumab in Crohn’s disease: a multicenter GETAID Study
- Author
-
Fumery, M, primary, Caron, B, additional, Hébuterne, X, additional, Altwegg, R, additional, Roblin, X, additional, Stefanescu, C, additional, Meyer, A, additional, Nachury, M, additional, Laharie, D, additional, Le Berre, C, additional, Guillo, L, additional, Biron, A, additional, Caillo, L, additional, Buisson, A, additional, Nancey, S, additional, Uzzan, M, additional, Vuitton, L, additional, Gilletta, C, additional, Geyl, S, additional, Simon, M, additional, Kirchgesner, J, additional, Ah Soune, P, additional, Duveau, N, additional, Vidon, M, additional, Abitbol, V, additional, Paupard, T, additional, Defrance, A, additional, and Peyrin-Biroulet, L, additional
- Published
- 2024
- Full Text
- View/download PDF
3. P386 Persistence of bowel urgency despite clinical remission after induction therapy is associated with unfavorable long-term outcomes in patients with ulcerative colitis: results from the multicenter UC-RGENCY study
- Author
-
Buisson, A, primary, Amiot, A, additional, Nachury, M, additional, Altwegg, R, additional, Serrero, M, additional, Guilmoteau, T, additional, Treton, X, additional, Caillo, L, additional, Vuitton, L, additional, Bouguen, G, additional, Pereira, B, additional, and Fumery, M, additional
- Published
- 2024
- Full Text
- View/download PDF
4. DOP05 Bowel damage and its correlation with the disability index in patients with recently diagnosed Crohn´s Disease
- Author
-
Revés, J, primary, Roager Madsen, G, additional, Burisch, J, additional, Wong, C, additional, Arebi, N, additional, Bonnet-Dodel, M, additional, Buisson, A, additional, Gatt, K, additional, Ellul, P, additional, Vieujean, S, additional, Ordas, I, additional, Duricova, D, additional, Rodríguez-Lago, I, additional, Sebastian, S, additional, Mocanu, I, additional, Kaimakliotis, I, additional, Goldis, A, additional, Hernandez, V, additional, Nachury, M, additional, Fumery, M, additional, Alloca, M, additional, Pedersen, N, additional, Barberio, B, additional, Guedes, A, additional, Ribeiro, R, additional, Ungaro, R, additional, Mary, J Y, additional, Bigot, N, additional, Lambert, J, additional, Colombel, J F, additional, and Torres, J, additional
- Published
- 2024
- Full Text
- View/download PDF
5. P943 Real world Effectiveness and safety of tofacitinib in patients with Ulcerative Colitis: 6 months follow-up of the French TOFAST study
- Author
-
Fumery, M, primary, Bouhnik, Y, additional, Faure, P, additional, Bouzidi, A, additional, Brault, Y, additional, Peyrin-Boroulet, L, additional, and Laharie, D, additional
- Published
- 2024
- Full Text
- View/download PDF
6. P408 Complete endoscopic healing, the future therapeutic target in Crohn's disease? Results of a prospective multicenter study
- Author
-
Yzet, C, primary, Brazier, F, additional, Derval, E, additional, Vaneslander, P, additional, Dejour, V, additional, Pricope, D, additional, Diouf, M, additional, and Fumery, M, additional
- Published
- 2024
- Full Text
- View/download PDF
7. P1151 Incidence and risk factors of thromboembolic events in Pediatric-Onset Inflammatory Bowel Disease: a population-based study
- Author
-
Richard, N, primary, Leroyer, A, additional, Ley, D, additional, Dupont, C, additional, Bertrand, V, additional, Wils, P, additional, Gower-Rousseau, C, additional, Turck, D, additional, Guillon, N, additional, Sarter, H, additional, Savoye, G, additional, and Fumery, M, additional
- Published
- 2024
- Full Text
- View/download PDF
8. P857 Effectiveness and safety of subcutaneous infliximab in perianal Crohn's disease: a multicentre cohort study
- Author
-
Andre, M, primary, Kirchgesner, J, additional, Laharie, D, additional, Guillo, L, additional, Abramowitz, L, additional, Seksik, P, additional, Nachury, M, additional, Fumery, M, additional, Amil, M, additional, Nancey, S, additional, Le Berre, C, additional, Moussata, D, additional, Buisson, A, additional, Fathallah, N, additional, Gilletta, C, additional, Uzzan, M, additional, Duveau, N, additional, Peyrin-Biroulet, L, additional, Nahon, S, additional, Savoye, G, additional, Charkaoui, M, additional, Vicaut, E, additional, and Vuitton, L, additional
- Published
- 2024
- Full Text
- View/download PDF
9. P275 Fecal calprotectin, intestinal ultrasound, and their combination for the diagnosis of Crohn’s disease
- Author
-
Fumery, M, primary, Dubian, S, additional, Brazier, F, additional, Buisson, A, additional, Meynier, J, additional, and Yzet, C, additional
- Published
- 2024
- Full Text
- View/download PDF
10. P1071 Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID
- Author
-
Caron, B, primary, Seksik, P, additional, Buisson, A, additional, Wils, P, additional, Savoye, G, additional, Stefanescu, C, additional, Laharie, D, additional, Guillo, L, additional, Abitbol, V, additional, Bonnet, J, additional, Altwegg, R, additional, Vuitton, L, additional, Moussata, D, additional, Bourreille, A, additional, Biron, A, additional, Gilletta, C, additional, Fumery, M, additional, Nahon, S, additional, Nancey, S, additional, Camara, H, additional, and Peyrin-Biroulet, L, additional
- Published
- 2024
- Full Text
- View/download PDF
11. P322 Compared Efficacy of Second-Line Treatments for Ulcerative Colitis After Failure of Vedolizumab in First-Line Treatment: A Retrospective Multicenter Study
- Author
-
Calmejane, L, primary, Reenaers, C, additional, Amiot, A, additional, Nuzzo, A, additional, Vuitton, L, additional, Altwegg, R, additional, Guillo, L, additional, Wils, P, additional, Roblin, X, additional, Le Cosquer, G, additional, Simon, M, additional, Benezech, A, additional, Laharie, D, additional, Fumery, M, additional, Buisson, A, additional, Charkaoui, M, additional, Nancey, S, additional, Sabra, G, additional, Geyl, S, additional, Coffin, B, additional, Cavicchi, M, additional, Le Berre, C, additional, Goutorbe, F, additional, Bouguen, G, additional, Vidon, M, additional, Christmann, P Y, additional, Kirchgesner, J, additional, and Uzzan, M, additional
- Published
- 2024
- Full Text
- View/download PDF
12. P360 Prevalence and risk factors for fatigue in patients with inflammatory bowel disease and endoscopic healing
- Author
-
Yzet, C, primary, Brazier, F, additional, Meudjo, E, additional, Robert, C, additional, Moreau, C, additional, Derval, E, additional, Richard, N, additional, and Fumery, M, additional
- Published
- 2024
- Full Text
- View/download PDF
13. DOP79 Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohort
- Author
-
Verstockt ., B, primary, Taelman, T, additional, Vavricka, S R, additional, Zabana, Y, additional, Lenfant, M, additional, Macaigne, G, additional, Maillard, M H, additional, Savarino, E, additional, Teich, N, additional, Kiudelis, V, additional, de la Revilla Negro, J, additional, Ribaldone, D G, additional, Barreiro-de Acosta, M, additional, Wildt, S, additional, Rivière, P, additional, Fumery, M, additional, Truyens, M, additional, Amiot, A, additional, Marsal, J, additional, Levartovsky, A, additional, Vieujean, S, additional, Somers, M, additional, Cremer, A, additional, Lutakov, I, additional, Cohen, N A, additional, Dewit, S, additional, Bajer, L, additional, Rahier, J F, additional, Backman, A S, additional, Nancey, S, additional, Choden, T, additional, Van Dongen, J, additional, Münch, A, additional, and Julsgaard, M, additional
- Published
- 2024
- Full Text
- View/download PDF
14. P1015 Subcutaneous infliximab effectively manages clinical outcomes of Inflammatory Bowel Disease independently of various confounding factors
- Author
-
Buisson, A, primary, Cummings, F, additional, Subramanian, S, additional, Rahmany, S, additional, Fumery, M, additional, Kwon, B, additional, Park, S, additional, Lee, Y N, additional, and Smith, P J, additional
- Published
- 2024
- Full Text
- View/download PDF
15. P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial
- Author
-
Vuitton, L, primary, Poullenot, F, additional, Bouhnik, Y, additional, Wils, P, additional, Buisson, A, additional, Viennot, S, additional, Bouguen, G, additional, Hébuterne, X, additional, Gilletta, C, additional, Nancey, S, additional, Bourreille, A, additional, Amil, M, additional, Altwegg, R, additional, Goutorbe, F, additional, Caillo, L, additional, Plastaras, L, additional, Brixi, H, additional, Simon, M, additional, Serrero, M, additional, Fumery, M, additional, Rahier, J F, additional, Vicaut, E, additional, and Peyrin-Biroulet, L, additional
- Published
- 2024
- Full Text
- View/download PDF
16. P318 Performance of rectosigmoidoscopy and rectoscopy to assess endoscopic and histological healing in ulcerative colitis
- Author
-
Yzet, C, primary, Moreau, C, additional, Chatelain, D, additional, Meudjo, E, additional, Brazier, F, additional, Hautefeuille, V, additional, Robert, C, additional, Decrombecque, C, additional, Sarba, R, additional, Pichois, R, additional, Michaud, A, additional, and Fumery, M, additional
- Published
- 2024
- Full Text
- View/download PDF
17. DOP23 The role of histology for the prediction of clinical relapse in Crohn’s Disease: A substudy of the STORI cohort
- Author
-
Reenaers Dr, C, primary, Enea, D, additional, Nachury, M, additional, Laharie, D, additional, Bouhnik, Y, additional, Fumery, M, additional, Gornet, J M, additional, Amiot, A, additional, Altwegg, R, additional, de Vos, M, additional, Marteau, P, additional, Bourreille, A, additional, Nancey, S, additional, Viennot, S, additional, Louis, E, additional, and svrcek, M, additional
- Published
- 2024
- Full Text
- View/download PDF
18. P733 Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases treated with intensified doses: the REMSWITCH-LT study
- Author
-
Buisson, A, primary, Nachury, M, additional, Bazoge, M, additional, Yzet, C, additional, Wils, P, additional, Dodel, M, additional, Coban, D, additional, Pereira, B, additional, and Fumery, M, additional
- Published
- 2024
- Full Text
- View/download PDF
19. P226 Disability in Crohn’s Disease Patients at diagnosis: Findings from the CROCO (Crohn´s Disease Cohort) study
- Author
-
Revés, J, primary, Roager Madsen, G, additional, Burisch, J, additional, Wong, C, additional, Arebi, N, additional, Bonnet-Dodel, M, additional, Buisson, A, additional, Gatt, K, additional, Ellul, P, additional, Vieujean, S, additional, Ordas, I, additional, Duricova, D, additional, Rodríguez-Lago, I, additional, Sebastian, S, additional, Mocanu, I, additional, Kaimakliotis, I, additional, Goldis, A, additional, Hernandez, V, additional, Nachury, M, additional, Fumery, M, additional, Alloca, M, additional, Pedersen, N, additional, Barberio, B, additional, Guedes, A, additional, Ribeiro, R, additional, Ungaro, R, additional, Mary, J Y, additional, Bigot, N, additional, Lambert, J, additional, Colombel, J F, additional, and Torres, J, additional
- Published
- 2024
- Full Text
- View/download PDF
20. P1122 Comorbidities Associated with Pediatric Onset Inflammatory Bowel Diseases: A Population-Based Study
- Author
-
Richard, N, primary, Leroyer, A, additional, Sarter, H, additional, Dupont, C, additional, Turck, D, additional, Bertrand, V, additional, Wils, P, additional, Gower-Rousseau, C, additional, Savoye, G, additional, Guillon, N, additional, Ley, D, additional, and Fumery, M, additional
- Published
- 2024
- Full Text
- View/download PDF
21. P1125 Incidence and Neoplastic Risk Associated with Colonic Stricture in Pediatric-Onset Crohn's Disease: A Population-based Study
- Author
-
Richard, N, primary, Leroyer, A, additional, Dupont, C, additional, Turck, D, additional, Bertrand, V, additional, Wils, P, additional, Gower-Rousseau, C, additional, Guillon, N, additional, Savoye, G, additional, Ley, D, additional, Sarter, H, additional, and Fumery, M, additional
- Published
- 2024
- Full Text
- View/download PDF
22. P231 Impact of the depth of mucosal healing on the burden of ulcerative colitis : a cross-sectional study
- Author
-
Yzet, C, primary, Brazier, F, additional, Robert, C, additional, Moreau, C, additional, Meudjo, E, additional, Richard, N, additional, Chatelain, D, additional, and Fumery, M, additional
- Published
- 2024
- Full Text
- View/download PDF
23. P712 Effectiveness of switching from intravenous to subcutaneous infliximab in Inflammatory Bowel Disease patients: A combined analysis of real-world evidence
- Author
-
Cummings, F, primary, Buisson, A, additional, Smith, P J, additional, Rahmany, S, additional, Subramanian, S, additional, Kwon, B, additional, Park, S, additional, Lee, Y N, additional, and Fumery, M, additional
- Published
- 2024
- Full Text
- View/download PDF
24. Long‐term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH‐LT study.
- Author
-
Buisson, A., Nachury, M., Bazoge, M., Yzet, C., Wils, P., Dodel, M., Coban, D., Pereira, B., and Fumery, M.
- Subjects
INFLAMMATORY bowel diseases ,DISEASE relapse ,INFLIXIMAB ,DISEASE remission - Abstract
Summary: Background: The long‐term risk of relapse after switching from intravenous (IV) to subcutaneous (SC) infliximab remains unknown in inflammatory bowel disease (IBD). Aims: To assess the long‐term effectiveness and acceptability of switching from IV to SC infliximab in patients with IBD treated with or without an intensified IV regimen. Methods: We extended the follow‐up of the REMSWITCH study including patients with IBD in clinical remission who were switched from IV to SC infliximab (120 mg/2 weeks). Relapse was defined as clinical relapse or faecal calprotectin increase ≥150 μg/g compared to baseline. Results: After median follow‐up of 18 [15–20] months, among 128 patients, rates of relapse were 13.8% (8/58), 18.4% (7/38), 35.3% (6/17) and 86.7% (13/15) at last follow‐up (p < 0.001), in those receiving 5 mg/kg/8 weeks, 10 mg/kg/8 weeks, 10 mg/kg/6 weeks and 10 mg/kg/4 weeks at baseline, respectively. Among relapsing patients, dose escalation led to clinical remission in 82.1% (23/28). In multivariable analyses, factors associated with higher risk of relapse were IV infliximab 10 mg/kg/4 weeks (OR = 61.0 [6.1–607.0], p < 0.001) or 10 mg/kg/6 weeks (OR = 4.7 [1.1–20.2], p = 0.017), and decreased (OR = 5.6 [1.5–20.3], p = 0.004) or stable (OR = 5.0 [1.6–15.0], p = 0.009) serum levels of infliximab between baseline and first post‐switch visit. Acceptability was improved at 6 months and did not decrease over time (6.9 ± 1.6 before the switch vs. 8.8 ± 1.3 at 6 months and 8.8 ± 1.3 at last follow‐up; p < 0.001). No severe adverse events were reported. Conclusions: Switching from IV to SC infliximab 120 mg every other week is safe and well accepted leading to low long‐term risk of relapse. Tight monitoring and dose escalation should be recommended for patients receiving 10 mg/kg/6 weeks and 4 weeks, respectively. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF Agent.
- Author
-
Fumery M, Serrero M, Bouguen G, Amiot A, Altwegg R, Nachury M, Vuitton L, Treton X, Caillo L, Pereira B, and Buisson A
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Remission Induction methods, Propensity Score, Treatment Outcome, Tumor Necrosis Factor Inhibitors therapeutic use, Colitis, Ulcerative drug therapy, Ustekinumab therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Gastrointestinal Agents therapeutic use
- Abstract
Background: Both vedolizumab and ustekinumab can be considered for the treatment of ulcerative colitis [UC], but head-to-head trials are lacking., Aim: We aimed to compare the effectiveness of vedolizumab and ustekinumab after anti-tumour necrosis factor [anti-TNF] failure in UC patients., Patients and Methods: In this multicentre study, we included consecutive adult patients with UC, with partial Mayo score >2 and prior anti-TNF exposure, treated with vedolizumab or ustekinumab between January 2019 and August 2022. Comparisons were performed using propensity score analyses [inverse probability of treatment weighting]., Results: Among a total of 293 patients included, 151 and 142 received vedolizumab and ustekinumab, respectively. After propensity score analysis, steroid-free clinical remission [SFCR] [partial Mayo score ≤2] was achieved at week 16 in 38.0% and 40.3% of patients treated with vedolizumab and ustekinumab, respectively (adjusted odds ratio [aOR] = 1.11, 95% confidence interval [0.39-3.13], p = 0.85). Rates of SFCR in patients exposed to one, two, and three lines of biologics/small molecules among patients treated with vedolizumab and ustekinumab were respectively 53.3% vs 62.1% [p = 0.52], 44.4% vs 33.8% [p = 0.52], and 2.6% vs 19.1% [p = 0.027]. Endoscopic remission [SFCR and endoscopic Mayo score ≤1] and histological remission [SFCR, endoscopic remission, and Nancy histological index ≤1] at week 16 were achieved in respectively 5.3% vs 17.5% (aOR = 3.77 [1.25-11.36], p = 0.018) and 2.1% vs 11.1% (aOR = 5.85 [1.47-23.30], p = 0.012) in the vedolizumab and ustekinumab groups. No difference regarding the risk of drug discontinuation between the two groups (aHR = 1.03 [0.51-2.08], p = 0.92) was observed. While no factor was identified for vedolizumab, primary failure to at least one biologic/small molecule (OR = 0.31 [0.11-0.82], p = 0.018) was significantly associated with a decreased rate of SFCR among patients treated with ustekinumab., Conclusion: While no difference in terms of short-term clinical remission was observed, ustekinumab appears to be more effective than vedolizumab in inducing endoscopic and histological remission at week 16 after failure of anti-TNFs in UC., (© The Author(s) 2024. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
26. Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.
- Author
-
Fautrel B, Bouhnik Y, Salliot C, Carbonnel F, Fumery M, Bernardeau C, Maugars Y, Flamant M, Coury F, Braithwaite B, Hateb S, and Addison J
- Abstract
Background: There is a need for published data on real-world use of SB5, an adalimumab (ADL) biosimilar approved in Europe in 2017, on the basis of evidence from pre-clinical and analytic data as well as phase I and III clinical studies demonstrating equivalent efficacy and comparable pharmacokinetics, safety and immunogenicity profiles as the reference ADL., Objectives: The purpose of this study was to estimate patient persistence on SB5 at 12 months post-initiation using clinical and healthcare claims data from the French Système National des Données de Santé (national healthcare claims database, SNDS) in addressing data gaps., Methods: PERFUSE is a 12-month, observational, multi-centre cohort study of patients with rheumatic or gastrointestinal immune-mediated inflammatory diseases (IMIDs) who initiated routine SB5 treatment between October 2018 and October 2020, either as their first ADL (naïve) or transitioning from another ADL (switched). Clinical data, including disease activity scores, C-reactive protein levels, and dosing information, were collected as available from patient records captured during routine visits to specialist physicians. Persistence data were supplemented with data from the French national healthcare claims database (SNDS). Analyses of clinical data were descriptive, while persistence was assessed using a Kaplan-Meier survival analysis., Results: Overall, 911 patients were included: 507 from rheumatology centres [116 with rheumatoid arthritis (RA), 78 psoriatic arthritis (PsA), and 313 ankylosing spondylitis (AS)] and 404 from gastroenterology centres [316 with Crohn's disease (CD) and 88 ulcerative colitis (UC)]. Among naïve patients, 12-month remission/low activity rates were 58% for RA, 66% for PsA, 59% for AS, 94% for CD, and 85% for UC, increasing significantly from baseline for all indications (p < 0.05). Switched patients' remission rates remained stable between baseline and month 12 (M12) for all indications (p > 0.05). Persistence (95% CI) at M12 among naïve patients was 59% (46.5, 68.8) for RA, 65% (49.7, 77.1) for PsA, 56% (48.3, 62.6) for AS, 70% (63.0, 75.7) for CD, and 42% (30.7, 53.1) for UC, compared to 60% (42.7, 73.7) for RA, 57% (37.3, 72.1) for PsA, 55% (45.8, 64.0) for AS, 63% (53.4, 71.7) for CD, and 56% (27.2, 77.6) for UC among switched patients. No significant differences were observed between naïve and switched patients (p > 0.05). SNDS pairing provided information on 68 of the 132 patients (52%) who were lost to follow-up in the clinical database, of whom 57 (84%) were confirmed persistent at M12 and 11 (16%) non-persistent. Primary treatment failure (naïve patients) and patient decision (switched patients) were the most common reasons stated for treatment discontinuation., Conclusions: SB5 provides clinically effective treatment of both gastrointestinal and rheumatic IMIDs for naïve and switched patients, with no loss of control observed when switching. Persistence was comparable between naïve and switched populations, though the reasons for non-persistence differed., Trial Registry: Trial registration number: Clinical Trials identifier NCT03662919. Trial registration date: 10 September 2018., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
27. Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective.
- Author
-
Parigi TL, Solitano V, Armuzzi A, Barreiro de Acosta M, Begun J, Ben-Horin S, Biedermann L, Colombel JF, Dignass A, Fumery M, Ghosh S, Kobayashi T, Louis E, Magro F, Panaccione R, Rausch A, Reinisch W, Selinger C, Jairath V, Danese S, and Peyrin-Biroulet L
- Abstract
Background: Mucosal healing (MH) is an established treatment goal in inflammatory bowel disease (IBD). However, various definitions of MH exist. We aimed to identify how MH is defined in randomized controlled trials (RCTs) in ulcerative colitis (UC) and Crohn's disease (CD)., Methods: We searched MEDLINE, EMBASE, and the Cochrane library from inception to December 2023 for phase 2 and 3 RCTs of advanced therapies in IBD., Results: One hundred forty-four studies were included, 72 in UC and 72 in CD, published between 1997 and 2023. In UC, 64% (46/72) RCTs reported MH as an endpoint. 12 definitions of MH were found, from endoscopic assessment alone (35/46; 76%) to the more recent combination of histology and endoscopy (10/46; 22%). 96% (44/46) of studies used the Mayo Endoscopic Subscore. In CD, reporting of MH lagged behind UC, with only 12% (9/72) of trials specifically defining MH as an endpoint, 7 as "absence of ulceration," 2 as Simplified Endoscopic Score for CD score ≤2 or 0. Histological assessment was performed in 3 RCTs of CD. Centralized reading of endoscopy was used in 48% (35/72) of RCTs of UC and 22% (16/72) of CD. Only 1 RCT included transmural healing as an endpoint., Conclusions: A standard definition of MH in IBD is lacking. Definitions have evolved particularly in UC, which now includes the addition of histological evaluation. Transmural healing holds promise as a future target in CD. We support a greater standardization of definitions as we expect endpoints to become increasingly stringent and multimodal with computers automating the assessment., (© 2024 The Author(s). United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.)
- Published
- 2024
- Full Text
- View/download PDF
28. Incidence and risk factors for thromboembolic events in pediatric-onset inflammatory bowel disease: A French population-based study.
- Author
-
Richard N, Leroyer A, Ley D, Dupont C, Bertrand V, Wils P, Gower-Rousseau C, Turck D, Guillon N, Sarter H, Savoye G, and Fumery M
- Abstract
Introduction: Patients with inflammatory bowel disease (IBD) are at higher risk of thromboembolic events (TE). In pediatric-onset IBD, more data on incidence and risk factors of venous (VTE) and arterial events (ATE) at the population level are needed to guide thromboprophylaxis., Methods: All patients aged ≤ 16 years diagnosed with Crohn's disease (CD) or ulcerative colitis (UC) between 1988 and 2011 in the prospective EPIMAD population-based registry were followed until 2013. Every TE occurring during the follow-up period was included., Results: A total of 1,344 patients were included: 1,007 with CD and 337 with UC, and a median diagnosis age of 14.3 years. After a median follow-up of 8.3 years, 2 (0.15 %) ATE and 15 (1.1 %) VTE occurred at median age of 20.4 years. The global incidence rate of thromboembolic events was 1.32 per 1000 person-years. Periods of active disease (HR=8.4, p = 0.0002), the 3-month-period following surgery (HR=16.4, p = 0.0002) and hospitalization (HR=21.7, p < 0.0001) were found to be associated with an increased risk of VTE. A lower rate of VTE was found in patients treated with 5-aminosalicylates (HR=0.1, p = 0.002)., Conclusion: The risk of TE was low in this population. VTE were strongly associated with active disease, surgery and hospitalization., Competing Interests: Conflict of interest The authors declare the following conflict of interest: M.F. has received lecture/consultant fees from AbbVie, Ferring, Tillotts, MSD, Biogen, Amgen, Fresenius, Hospira, Sandoz, Pfizer, Celgene, Gilead, Boehringer, Galapagos, Janssen, and Takeda. C.D. has received consultant fees from AbbVie. N.R. has received lecture/consultant fees from AbbVie and Takeda. The other authors state that they have no competing interests regarding this work to disclose., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. [Recto-colic graft-versus-host disease (GVH). Diagnostic and prognostic criteria in a cohort of patients from Amiens university hospital].
- Author
-
Ducloux-Lebon B, Lebon D, Tesson JR, Fumery M, Marolleau JP, and Chatelain D
- Abstract
Introduction: Recto-colic graft-versus-host disease (GVHD) is a frequent and serious complication of hematopoietic stem cell allogeneic transplantation, which is sometimes difficult to diagnose. The aim of our study was to identify histological diagnostic and prognostic criteria for recto-colic GVH., Material and Method: Patients allografted at Amiens university hospital from 2012 to 2017 were retrieved. Those who had a recto-colic biopsy were included and divided into two groups (final diagnosis of GVH and non-GVH), then biopsies were reviewed by 2 pathologists., Results: One hundred and nineteen patients were included. Sixty-seven were allocated to the GVH group and 52 to the non-GVH group. In the GVH group, we observed a significantly greater number of apoptotic bodies (AB) on standard HES staining and with the anti-Caspase 3 immunohistochemistry, cryptolytic AB abscesses, atrophy, regenerative glands and glands lined with eosinophilic cells (P<0.001). Anti-Caspase 3 immunohistochemistry revealed more AB than standard HES staining (P<0.005). But to differentiate GVH cases from non-GVH cases, we obtained a threshold value of 3.5 AB per 10 contiguous crypts on standard HE staining and with the anti-Caspase 3 immunohistochemistry. From 4 AB per 10 contiguous crypts, on HES staining and anti-Caspase 3 immunostaining, the diagnosis of GVH became consistent. No non-GVH case had more than 6 AB per 10 contiguous crypts. GVH patients with more than 8 AB per 10 contiguous crypts had a worse prognosis (P<0.001)., Conclusion: We confirm the value of AB and their counting in the diagnosis of GVH, with a diagnostic threshold of 4 AB and a prognostic threshold of 8 AB. Glands lined with eosinophilic cells could be an additional diagnostic criterion in favor of GVH to be confirmed by further studies., (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
30. Disease burden of patients with moderate to severe ulcerative colitis: A French multicenter real-life study (THEFAR).
- Author
-
Fumery M, Altwegg R, Aygalenq P, Filippi J, Ghestem V, Jamonneau I, Kirion J, Bouée S, and Robert C
- Abstract
Background: Specific studies on the impact of ulcerative colitis (UC) and bowel urgency (BU) on disability and quality of life (QoL) of patients on advanced therapies are missing., Methods: Clinical and therapeutic management data were collected by Gastroenterologists from adult patients with UC treated with advanced therapies. Patients reported outcomes on QoL were collected using patient-reported questionnaires., Results: Forty-one sites enrolled 293 patients. Median age was 42.0 years, median disease duration was 6.0 years. 38.9 % had active disease (partial Mayo score>1). Median treatment duration was 16.9 months. 166 (57.0 %) patients had BU [median UNRS=2] and 78.3 % had fecal incontinence [median Wexner score=8.0]. Moderate to severe disability (IBD-Disk score≥40) was reported in 37.8 % patients. BU patients had a higher Wexner score [10.0 vs 5.2, p < 0.0001] and moderate to severe disability rate (53.7% vs 16.9 %, p < 0.0001), lower QoL and work productivity than those in BU remission: mean EQ-5D-5 L utility [0.846 vs 0.943, p < 0.0001], VAS for self-rated health [66.2 vs 82.1, p < 0.0001], and overall work impairment [35.7% vs 11.3 %, p < 0.0001]., Conclusion: The burden of moderate to severe UC, especially in patients with BU, is high. These findings highlight that BU control remains an unmet medical need in UC patients and underscore the need for new innovative treatments., Competing Interests: Conflicts of interest Justin Kirion and Stéphane Bouée are employed by CEMKA who received an unrestricted grant to perform the study. Camille Robert, Vincent Ghestem and Isabelle Jamonneau are employed by the company Lilly. Mathurin Fumery Consultant for Abbvie, Sandoz, Celltrion, Arena, MSD, Lilly, Pfizer, Ferring, Tillots, Takeda, Amgen, Biogen, Fresenius, and Nordic Pharma. Romain Altwegg: Advisory boards for Abbvie, Takeda, Galapagos, Amgen, Sandoz, Lilly, Pfizer, and Janssen. Jérome Filippi: Abbvie, Amgen Biogen, Celltrion, Galapagos, Janssen, MSD, Pfizer, Sandoz, and Takeda. Philippe Aygalenq: Philippe Aygalenq: Consultant for Janssen Cilag, Pfizer, MSD, Abbvie, and Takeda., (Copyright © 2024 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
31. Farming Activities and Risk of Inflammatory Bowel Disease: A French Nationwide Population-based Cohort Study.
- Author
-
Petit P, Leroyer A, Chamot S, Fumery M, and Bonneterre V
- Subjects
- Humans, Male, France epidemiology, Female, Adult, Middle Aged, Crohn Disease epidemiology, Risk Factors, Cohort Studies, Farmers statistics & numerical data, Pesticides adverse effects, Occupational Exposure adverse effects, Occupational Exposure statistics & numerical data, Inflammatory Bowel Diseases epidemiology, Colitis, Ulcerative epidemiology, Agriculture statistics & numerical data
- Abstract
Background and Aims: Epidemiological data regarding inflammatory bowel disease [IBD] are lacking, in particular for occupationally exposed populations. We investigated whether, among the entire French farm manager [FM] workforce, certain agricultural activities are more strongly associated with IBD than others., Methods: Nationwide, population-based, insurance claims and electronic health records from all FMs who worked at least once over the period 2002-2016 were used [n = 1 088 561, 69% males]. The outcome measure was the association between 26 farming activities and the risk of IBD, Crohn's disease [CD], and ulcerative colitis [UC], measured as hazard ratios [HRs], after adjusting for age, sex, pre-existing medical comorbidities, and farm location. The time to first chronic disease declaration was used as the underlying time scale. A model was generated for every activity and disease, using a reference group comprising all FMs who abstained from the specified activity from 2002 to 2016., Results: There were 1752 IBD cases, with 704 CD [40.2%] and 1048 UC [59.8%] cases, respectively. Elevated HRs were observed for fruit arboriculture [HR from 1.17 to 1.52] and dairy farming [HR from 1.22 to 1.46] for all IBD, in crop farming for CD only (HR = 1.26, 95% confidence interval [CI]: 1.06-1.49), and in shellfish farming [HR from 2.12 to 2.51] for both CD and IBD., Conclusions: Further research regarding specific farming activities and exposures likely to modify the microbiota [eg, pesticides, pathogens] is required to identify potential occupational risk factors [agricultural exposome] for IBD. Exposure to Mycobacterium avium subspecies paratuberculosis, Cryptosporidium, environmental toxins, micro/nanoplastics, and pesticides represents promising research avenues., (© The Author(s) 2024. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.)
- Published
- 2024
- Full Text
- View/download PDF
32. Factors associated with decreased ovarian reserve in Crohn's disease: A systematic review and meta-analysis.
- Author
-
Foulon A, Richard N, Guichard C, Yzet C, Breuval C, Gondry J, Cabry-Goubet R, Michaud A, and Fumery M
- Subjects
- Humans, Female, Adult, Crohn Disease blood, Crohn Disease physiopathology, Ovarian Reserve physiology, Anti-Mullerian Hormone blood
- Abstract
Introduction: It is still unclear whether Crohn's disease (CD) might be associated with diminished ovarian reserve (OvR) and factors influencing anti-Mullerian hormone (AMH) levels in CD are poorly known., Material and Methods: We conducted a comprehensive literature search of multiple electronic databases from inception to June 2022 to identify all studies reporting AMH levels or factors associated with diminished OvR in patients with CD., Results: Of the 48 studies identified in our search, eight (including 418 patients with CD) were finally included. The mean difference (95% confidence interval [CI]) in the AMH level between pooled CD patients and controls was -0.56 (-1.14 to 0.03) (p = 0.06). A history of CD-related surgery was not associated with a lower OvR (odds ratio, OR [95% CI] 1.34, [0.66-2.7]; p = 0.4). While disease activity and perianal disease seems associated with a low OvR, disease location (L2 vs. L1, OR [95% CI] = 95% CI [0.47-7.4]; p = 0.4) and L3 vs. L1 (OR [95% CI] = 1.44 [0.67-3.12]; p = 0.3), CD medication, and disease behavior were not., Conclusions: Our systematic review and meta-analysis did not identify a significantly low OvR in patients with CD. Contrary to CD-related surgery risk factor, active disease was associated lower AMH levels., (© 2024 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).)
- Published
- 2024
- Full Text
- View/download PDF
33. Emerging role of environmental pollutants in inflammatory bowel disease risk, outcomes and underlying mechanisms.
- Author
-
Estevinho MM, Midya V, Cohen-Mekelburg S, Allin KH, Fumery M, Pinho SS, Colombel JF, and Agrawal M
- Abstract
Epidemiological and translational data increasingly implicate environmental pollutants in inflammatory bowel disease (IBD). Indeed, the global incidence of IBD has been rising, particularly in developing countries, in parallel with the increased use of chemicals and synthetic materials in daily life and escalating pollution levels. Recent nationwide and ecological studies have reported associations between agricultural pesticides and IBD, particularly Crohn's disease. Exposure to other chemical categories has also been linked with an increased risk of IBD. To synthesise available data and identify knowledge gaps, we conducted a systematic review of human studies that reported on the impact of environmental pollutants on IBD risk and outcomes. Furthermore, we summarised in vitro data and animal studies investigating mechanisms underlying these associations. The 32 included human studies corroborate that heavy and transition metals, except zinc, air pollutants, per- and polyfluorinated substances, and pesticides are associated with an increased risk of IBD, with exposure to air pollutants being associated with disease-related adverse outcomes as well. The narrative review of preclinical studies suggests several overlapping mechanisms underlying these associations, including increased intestinal permeability, systemic inflammation and dysbiosis. A consolidated understanding of the impact of environmental exposures on IBD risk and outcomes is key to the identification of potentially modifiable risk factors and to inform strategies towards prediction, prevention and mitigation of IBD., Competing Interests: Competing interests: MF reports receiving lecture/consultant fees from Abbvie, Ferring, Tillots, MSD, Biogen, Amgen, Fresenius, Hospira, Sandoz, Pfizer, Bristol Myers Squibb, Celgene, Gilead, Boehringer, Eli Lilly, Nordic-Pharma, Arena, Galapagos, Janssen and Takeda. JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Ferring Pharmaceuticals, Shire and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Glaxo Smith Kline, Geneva, Iterative Scopes, Janssen Pharmaceuticals, Kaleido Biosciences, Landos, Otsuka, Pfizer, Prometheus, Sanofi, Takeda, TiGenix and hold stock options in Intestinal Biotech Development.MA reports consulting for Douglas Pharmaceutical., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
34. The GETAID: 40 years of a family story in IBD.
- Author
-
Laharie D, Vuitton L, Bourreille A, Bouhnik Y, Colombel JF, Louis E, Fumery M, Mailhat C, Mary JY, and Peyrin-Biroulet L
- Abstract
The Groupe d'Etude sur les Affections Inflammatoires Digestives (GETAID) was founded in Paris in 1983 by Professor R Modigliani and colleagues. From the beginning, the aim of this international (France, Belgium and Switzerland), multicentre, French-speaking group was to address clinical questions raised by patients or physicians in their daily practice or the inflammatory bowel diseases community, by focusing on clinical research on treatments through randomised controlled trials, prospective cohorts and cross-sectional studies, quantifying the severity of various facets of the disease when necessary for these studies. This approach very innovative has contributed to the advancement of knowledge in inflammatory bowel diseases by publishing more than 120 original articles in peer-reviewed journals throughout the GETAID 40-year history, most of them in top publications in gastroenterology and hepatology journals. In this paper, we will see what GETAID's contribution has been over the last four decades, review reasons for success and forthcoming challenges., (© The Author(s) 2024. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
35. Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID.
- Author
-
Caron B, Seksik P, Buisson A, Wils P, Savoye G, Stefanescu C, Laharie D, Guillo L, Abitbol V, Bonnet J, Altwegg R, Vuitton L, Moussata D, Bourreille A, Biron A, Gilletta C, Fumery M, Nahon S, Nancey S, Camara H, and Peyrin-Biroulet L
- Abstract
Background: Several adalimumab preparations are now available for patients with inflammatory bowel disease (IBD). Comparative satisfaction and tolerability are unknown., Objectives: This study investigated IBD patient satisfaction with approved adalimumab biosimilars and their originator., Design: In this cross-sectional study, we included 941 consecutive adalimumab-treated patients with IBD across 45 centres affiliated with the Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif who completed a satisfaction questionnaire comprising four items each rated by a 10-point scale., Methods: The differences in responses were performed using a one-way analysis of variance followed by Tukey's honest significant difference test., Results: The most commonly used drugs at inclusion were Humira
® (436/941, 46.3%), Amgevita® (177/941, 18.8%) and Hulio® (105/941, 11.2%). The mean overall satisfaction rate with adalimumab was 8.5 (standard deviation 1.8). Overall satisfaction was significantly higher in patients treated with Humira (8.6 (1.5)), Hulio (8.6 (1.8)) or Amgevita (8.5 (1.4)) ( p < 0.05). Satisfaction with the subcutaneous injection form was higher for patients treated with Yuflyma® (9.0 (1.4)), Humira (8.9 (1.3)) and Hulio (8.9 (1.7)) ( p < 0.05). A total of 299 patients (31.8%) described injection site reactions. In all, 223 patients (23.7%) reported being previously treated with another adalimumab of which (32/223, 14.3%) discontinued treatment due to side effects., Conclusion: In this real-world setting, patients with IBD had a high level of satisfaction with adalimumab treatment, with some differences in terms of overall satisfaction and satisfaction with the injection device., Competing Interests: B. Caron reports lecture and/or consulting fees from Abbvie, Amgen, Celltrion, Ferring, Galapagos, Janssen, Lilly and Takeda. P. Seksik received consulting fees from Takeda, Abbvie, Merck-MSD, Biocodex, Janssen, Amgen, Astellas and Pfizer and grants from Biocodex and Janssen. A. Buisson declares consulting fees from Abbvie, Amgen, Arena, Biogen, Celltrion Healthcare, CTMA, Galapagos, Janssen, MSD, Nexbiome, Pfizer, Roche, Takeda and Tillotts; lecture fees for Abbvie, Amgen, Biogen, Galapagos, Janssen, Mayoli-Spindler, MSD, Norgine, Pfizer, Roche, Takeda, Tillotts and Vifor Pharma; research grants from Abbvie, Celltrion Healthcare Janssen, Lilly, Pfizer and Takeda. P. Wils declares lecture and/or consulting fees from Abbvie, Biogen, Celltrion Ferring, Janssen, Pfizer, Lilly, Takeda and Amgen. G. Savoye reports travel from Janssen. C. Stefanescu declares lecture and/or consulting fees from Abbvie, Amgen, Biogen, Celltrion Ferring, Gilead, Janssen, Pfizer, Lilly, Takeda, Tillots. D. Laharie declares counselling, boards, transports or fees from Abbvie, Amgen, Biogen, Celltrion, Ferring, Galapagos, Janssen, Lilly, MSD, Pfizer, Prometheus, Roche, Takeda. L. Guillo declares consulting fees for Abbvie. V. Abitbol has received lecture fees from Amgen, Biogen, Mylan, Sandoz, Pfizer, Takeda, Janssen, Tillots, Gilead, Ferring. J. Bonnet reports fees from Galapagos, Celltrion Healthcare and Fresenius Kabi. R. Altwegg declares counselling, boards, transports or fees from Abbvie, Amgen, Biogen, Ferring, Janssen, MSD, Pfizer, Takeda, Tillotts. L. Vuitton declares lecture and/or consulting fees from Abbvie, Amgen, Viatris, MSD, Ferring, Celltrion, Galapagos, Takeda, Pfizer, Janssen, Lilly, Dr Falk pharma. D. Moussata reports lecture and/or consulting fees from Abbvie, Amgen, Galapagos, Janssen, Takeda, Sanofi, Fuji, Cellvizio. A. Bourreille reports lecture and/or consulting fees from AbbVie, Celltrion, Ferring, Galapagos, Janssen, Lilly, MSD, OSE Immunotherapeutics, Pfizer, Takeda, Tillots, Viatris. A. Biron reports no conflict of interest. C. Gilletta reports lecture and/or consulting fees from Abbvie, Amgen, Celltrion, Galapagos, Janssen, Pfizer and Takeda. M. Fumery has participated in advisory boards and as an educational speaker (personal fees) for AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celgene, Celltrion, CTMA, Ferring, Fresenius, Galapagos, Janssen, MSD, Takeda, Tillotts, Pfizer, Sandoz and Viatris and has received research grants from Fresenius, Janssen and Pfizer. S. Nahon declares lecture and/or consulting fees from Abbvie, Amgen, Viatris, MSD, Ferring, Celltrion, Galapagos, Takeda, Pfizer, Janssen, Lilly, Ferring, Biogen. S. Nancey reports lecture and/or consulting fees from Abbvie, Amgen, Celltrion, Ferring, Galapagos, Janssen, Lilly, Takeda, Novartis and Pfizer. H. Camara declares no conflict of interest. L. Peyrin-Biroulet reports lecture and/or consulting fees from AbbVie, Adacyte, Alimentiv, Alma Bio Therapeutics, Amgen, Applied Molecular Transport, Arena, Biogen, BMS, Celltrion, CONNECT Biopharm, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, HAC-Pharma, IAG Image Analysis, Index Pharmaceuticals, Inotrem, Janssen, Lilly, Medac, Mopac, Morphic, MSD, Norgine, Nordic Pharma, Novartis, OM Pharma, ONO Pharma, OSE Immunotherapeutics, Pandion Therapeutics, Par’Immune, Pfizer, Prometheus, Protagonist, Roche, Sanofi, Sandoz, Takeda, Theravance, Thermo Fisher, Tigenix, Tillots, Viatris, Vifor, Ysopia, Abivax, Samsung, Ventyx, Roivant and Vectivbio., (© The Author(s), 2024.)- Published
- 2024
- Full Text
- View/download PDF
36. Obstetric outcomes of patients with inflammatory bowel disease.
- Author
-
Tondreau A, Breuval C, Gondry J, Fumery M, and Foulon A
- Subjects
- Humans, Female, Pregnancy, Adult, Premature Birth epidemiology, Colitis, Ulcerative complications, Colitis, Ulcerative epidemiology, Colitis, Ulcerative therapy, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases epidemiology, Inflammatory Bowel Diseases therapy, France epidemiology, Infant, Newborn, Retrospective Studies, Young Adult, Cesarean Section statistics & numerical data, Pregnancy Complications epidemiology, Pregnancy Outcome epidemiology, Crohn Disease complications, Crohn Disease epidemiology, Crohn Disease therapy
- Abstract
Introduction: Inflammatory bowel diseases (IBD) are frequently diagnosed between the ages of 20 and 40, i.e. the most fertile period for women. The potential impact of IBD on pregnancy is therefore a frequent issue., Study Objective: To determine the impact of disease activity during pregnancy on the obstetric prognosis of women with IBD., Methods: Gastroenterological and obstetric data were collected for patients for all consecutive patients with IBD and pregnancy followed up at Amiens University Hospital (Amiens, France) between 2007 and 2021. Obstetrics outcome of patients with and without active disease were compared., Results: One hundred patients were included (81 with Crohn's Disease for 198 pregnancies, 19 with Ulcerative Colitis for 37 pregnancies). Patients with active IBD (21 patients, 24 pregnancies) were more likely to be admitted to hospital during pregnancy (66.6, vs. 5.2% in the inactive IBD group; p < 0.001), to give birth prematurely (mean term: 36.77 weeks of amenorrhoea (WA) vs. 38.7 WA, respectively; p = 0.02) and to experience very premature delivery (before 32 WA: 12.5 vs. 1.4%, respectively; p = 0.02). Patients with active disease had a shorter term at birth (38.4 WA, vs. 39.8 WA in the inactive disease group; p < 0.0001), a lower birth weight (2707 g vs. 3129 g, respectively; p = 0.01) and higher caesarean section rate (54.2 vs. 16.9%, respectively; p = 0.03)., Conclusion: Women with IBD patients are at risk of pregnancy related complications, especially when IBD is active. Controlling disease activity at conception and close monitoring of the pregnancy is essential to improve both gastroenterological and obstetric outcome., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
37. Non-invasive evaluation of mucosal healing by intestinal ultrasound or fecal calprotectin is efficient in Crohn's disease: A cross-sectional study.
- Author
-
Yzet C, Brazier F, Hautefeuille V, Richard N, Decrombecque C, Sarba R, Aygalenq P, Venezia F, Buisson A, Pichois R, Michaud A, and Fumery M
- Subjects
- Humans, Female, Male, Adult, Cross-Sectional Studies, Middle Aged, Prospective Studies, Colonoscopy, Ultrasonography, Wound Healing, Crohn Disease diagnostic imaging, Leukocyte L1 Antigen Complex analysis, Intestinal Mucosa diagnostic imaging, Intestinal Mucosa metabolism, Feces chemistry
- Abstract
Introduction: Endoscopy is still the gold, standard for assessing disease activity in Crohn's disease (CD). Its invasiveness, poor acceptability, and cost limit its use in the era of tight control and treat-to-target management. Fecal calprotectin (FC) and intestinal ultrasound (IUS) are non-invasive alternatives to colonoscopy to assess disease activity. We aimed to evaluate the performance of IUS and FC to assess mucosal healing in CD., Methods: All consecutive CD patients who underwent colonoscopy for mucosal healing assessment and IUS and/or FC within four weeks between September 2019 and April 2022 were included in a prospective cohort. The bowel-wall thickness (BWT) and color Doppler signal (CDS) were assessed for each segment. Endoscopic remission was defined by a CDEIS score < 3., Results: In total, 153 patients were included, of whom 122 showed endoscopic mucosal healing. Eighty-two (53.6 %) were female, the median was age 36 years (IQR, 28-46), and the median disease duration was 10 years (IQR, 4-19). The sensitivity (Se), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV) of a BWT < 3 mm to predict endoscopic mucosal healing were 56 %, 88 %, 95 %, and 36 %, respectively (patients misclassified as mucosal healing, 2.5 %). The best FC threshold (< 92.9 µg/g) provided similar results: 77 %, 89 %, 96 %, and 67 %, respectively (patients misclassified, 2.2 %). The association of an FC < 250 µg/g with a BWT < 3 mm and the absence of CDS increased the Sp and PPV: Se 58 %, Sp 95 %, PPV 97 %, VPN 43 %; patients misclassified, 1.3 %., Conclusion: Noninvasive evaluation of mucosal healing by IUS or calprotectin efficiently identifies patients with CD who have achieved endoscopic mucosal healing., Competing Interests: Declaration of competing interest CY: consultant and lecture fees from Abbvie, Takeda, Janssen, Amgen, and Galapagos MF: consultant and lecture fees from Abbvie, Takeda, Janssen, Amgen, Galapagos, Gilead, Biogen, Fresenius, Pfizer, Lilly, Celltrion, Ferring, Tillots, and Nordic Pharma VH: AAA, Merck KGaA, Amgen, Servier, Deciphera, Ipsen, and Pierre Fabre The other authors have nothing to declare., (Copyright © 2024 Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
38. Intestinal Ultrasound, Fecal Calprotectin, and Their Combination to Predict Endoscopic Mucosal Healing in Ulcerative Colitis: A Real-Life Cross-Sectional Study.
- Author
-
Yzet C, Meudjo E, Brazier F, Hautefeuille V, Moreau C, Robert C, Decrombecque C, Sarba R, Pichois R, Richard N, Meynier J, and Fumery M
- Abstract
Background: The development of noninvasive markers to assess mucosal healing in ulcerative colitis (UC) is essential in the treat-to-target era. The aim of this study was to evaluate the performance of intestinal ultrasound (IUS), fecal calprotectin (FC), and their combination to assess mucosal healing in UC patients., Methods: All consecutive patients between January 2021 and September 2022 with UC who underwent a complete colonoscopy and IUS and/or an FC test within 4 weeks were included in a prospective cohort. Bowel wall thickness (BWT) and the color Doppler signal (CDS) were assessed for each segment. Endoscopic mucosal healing was defined by a Mayo score of 0 to 1., Results: A total of 61 patients were included, of whom 79% showed endoscopic healing (26 Mayo 0 and 11 Mayo 1). Among the patients, 16 (27.6%) of 58 had a BWT <3 mm, and 41 (70.7%) of 58 had no CDS. The sensitivity, specificity, positive predictive value, and negative predictive value of a BWT <3 mm to predict endoscopic mucosal healing were 37%, 77%, 72%, and 44%, respectively. The association of FC <150 µg/g, a BWT <3 mm, and a CDS = 0 increased the specificity and positive predictive value (sensitivity 33%, specificity 94%, positive predictive value 89%, negative predictive value 48%). The combination of a normal IUS, no rectal bleeding, and an FC <172 µg/g identified all patients with mucosal healing., Conclusion: The combination of IUS and FC is effective in identifying mucosal healing in UC. Noninvasive evaluation of mucosal healing is possible for most UC patients., (© The Author(s) 2024. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
39. [Risk factors for high-grade squamous intraepithelial lesions or cervical cancer in chronic inflammatory bowel disease].
- Author
-
Dujardin C, Balcaen T, Vanoost A, Chatelain D, Gondry J, Fumery M, and Foulon A
- Subjects
- Humans, Female, Risk Factors, Retrospective Studies, Case-Control Studies, Adult, Middle Aged, Chronic Disease, Squamous Intraepithelial Lesions pathology, Uterine Cervical Neoplasms pathology, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases pathology
- Abstract
Introduction: Chronic inflammatory bowel disease (IBD) is thought to increase the risk of high-grade histological intraepithelial lesions (HGIL) and cervical cancer. The risk factors for developing these lesions are poorly understood., Materials and Methods: This is a single-center retrospective case-control study including IBD patients followed at our University Hospital Center from 2011 to 2021 who presented with HGIL or cervical cancer. Four controls were case-matched according to IBD type, age, active smoking and multiparity., Results: Eighteen cases and 72 controls were included. We found no significant differences between the 2 groups with regard to mean age at IBD diagnosis, mean duration of IBD, IBD location, history of IBD-related surgery or even association with another chronic inflammatory disease. In our study, the use of immunosuppressants/biotherapies in these patients [50% (9/18) for cases vs. 56% (40/72) for controls; P=0.9] was not a risk factor for IGRA or cervical cancer. Similarly, neither the total duration of exposure to immunosuppressants/biotherapies (9.9±8years for cases vs. 6.6±5.3years for controls; P=0.1), nor combined therapies [11% (2/18) for cases vs. 6% (4/72) for controls; P=0.3], nor azathioprine or methotrexate use [22% (4/18) for cases vs. 11% (8/72) for controls; P=0.3] were found to be risk factors., Conclusion: In our study, we found no risk factors for patients with IBD to develop IGRA or cervical cancer., (Copyright © 2024 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
40. Long-Term Neoplastic Risk Associated With Colorectal Strictures in Crohn's Disease: A Multicenter Study.
- Author
-
Hunaut T, Peyrin-Biroulet L, Le Bozec A, Germain A, Gower-Rousseau C, Sabbagh C, Cadiot G, and Fumery M
- Abstract
Background and Aims: While the occurrence of colonic stricture in Crohn's disease (CD) always raises concerns about the risk of cancer, the neoplastic risk associated with its stricture remains poorly known., Methods: All consecutive patients with colorectal stricture complicating CD in 3 academic centers between 1993 and 2022 were included in a retrospective cohort. We collected clinical, endoscopic, surgical, and pathology data and information on outcomes. Factors associated with neoplastic stricture were investigated by logistic regression., Results: A total of 88 patients (median age, 25 [interquartile range {IQR}, 19-37] years and median disease duration 12 [4-19] years) with 96 colorectal strictures were included. Strictures were nonpassable by the scope in 61.4% (n = 54) of cases, 70.5% (n = 62) were ulcerated, and 62.5% (n = 55) were symptomatic. Colonic resection and endoscopic balloon dilatation were needed in 47.7% (n = 42) and 28.6% (n = 12) of patients, respectively. After a median follow-up of 21.5 months (IQR [5.5-46.5]), 7 (8%) patients were diagnosed with neoplasia at the colonic stricture site (colonic adenocarcinoma, n = 5; neuroendocrine carcinoma, n = 1; and B-cell lymphoproliferative neoplasia, n = 1), with a median stricture duration at colorectal neoplasia diagnosis of 0 month (IQR [0.0-5.5]). While neoplastic strictures were diagnosed in older patients (58 vs 39 years), with longer disease duration (18 vs 11 years) and frequent obstructive symptoms (57.1% vs 11.1%), no patient-related or stricture-related factor was associated with neoplastic stricture in multivariate analysis., Conclusion: Eight percent of patients with colonic stricture complicating CD developed colorectal cancer. Colorectal cancer and stricture were often diagnosed at the same time and we did not report malignant stricture after 1 year of follow-up., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
41. Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID Study.
- Author
-
Fumery M, Caron B, Hébuterne X, Altwegg R, Roblin X, Stefanescu C, Meyer A, Nachury M, Laharie D, Le Berre C, Guillo L, Biron A, Caillo L, Buisson A, Nancey S, Uzzan M, Vuitton L, Gilletta C, Geyl S, Blain A, Kirchgesner J, Ah-Soune P, Duveau N, Vidon M, Abitbol V, Paupard T, Tran-Minh ML, Defrance A, and Peyrin-Biroulet L
- Abstract
Background & Aims: The aim of this study was to assess the long-term effectiveness and safety of risankizumab maintenance treatment in a large real-world cohort of patients with Crohn's Disease (CD)., Methods: From May 2021 to August 2023, all consecutive patients with CD treated with risankizumab in 25 GETAID centers have been retrospectively included. The primary endpoint was steroid-free clinical remission (Harvey Bradshaw Index [HBI] <5) at 52 weeks., Results: Of the 174 patients included, 99%, 93%, and 96% had been previously exposed to anti-TNF, vedolizumab, and ustekinumab, respectively. All patients had received ≥3 biologics, and 108 (62%) had previous intestinal resection. Median follow-up was 13.7 months (interquartile range, 10.0-18.1 months). The rates of steroid-free clinical remission and clinical remission at week 26 were 47% (72/152) and 52% (79/152), and 46% (58/125), and 48% (60/125) at week 52, respectively. Risankizumab persistence rates were 94%, 89%, and 79% at weeks 12, 26, and 52, respectively. At the end of follow-up, 45 (45/174; 26%) patients had discontinued risankizumab (loss of response, 42%; primary failure, 37%; intolerance, 13%). Thirty-six patients (36/174; 20.9%) were hospitalized, and 22 (22/174; 12.6%) required intestinal resection. Fifty-one patients (29%) had an adverse event, including 26 (15%) serious adverse events (CD flare, n = 17). One death (myocardial infarction) and one cancer (papillary thyroid carcinoma) were observed., Conclusion: This is the first real-life study to report long-term outcomes in patients with refractory CD treated with risankizumab. One-half of the patients achieved steroid-free clinical remission after 1 year, and the safety profile was consistent with the literature., (Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
42. Efficacy of ferric carboxymaltose on haemoglobin response among older patients with gastrointestinal bleeding: a randomised clinical trial.
- Author
-
Richard N, Arab-Hocine N, Vannier M, Leblanc-Boubchir R, Pelaquier A, Boruchowicz A, Musikas M, Amil M, Fumery M, Nahon S, Arotcarena R, Gelsi E, Maurin A, Hébuterne X, and Savoye G
- Subjects
- Humans, Male, Female, Aged, Aged, 80 and over, Double-Blind Method, Treatment Outcome, Prospective Studies, Hematinics adverse effects, Hematinics administration & dosage, Hematinics therapeutic use, France, Injections, Intravenous, Age Factors, Ferric Compounds adverse effects, Ferric Compounds administration & dosage, Ferric Compounds therapeutic use, Maltose analogs & derivatives, Maltose administration & dosage, Maltose adverse effects, Maltose therapeutic use, Hemoglobins metabolism, Hemoglobins analysis, Gastrointestinal Hemorrhage drug therapy, Quality of Life
- Abstract
Background: Acute gastrointestinal bleeding (AGIB) is common in older patients but the use of iron in this context remains understudied., Aims: This study aimed to evaluate prospectively the efficacy of ferric carboxymaltose to treat anaemia in older patients after AGIB., Methods: This randomised double-blinded placebo-controlled clinical trial was conducted in 10 French centres. Eligible patients were 65 years or more, had controlled upper or lower gastrointestinal bleeding and a haemoglobin level of 9-11 g/dl. Patients were randomly assigned, in a 1:1 ratio, to receive either one intravenous iron injection of ferric carboxymaltose or one injection of saline solution. The primary endpoint was the difference in haemoglobin level between day 0 and day 42. Secondary endpoints were treatment-emergent adverse events, serious adverse events, rehospitalisation and improvement of quality of life (QOL) at day 180., Results: From January 2013 to January 2017, 59 patients were included. The median age of patients was 81.9 [75.8, 87.3] years. At day 42, a significant difference in haemoglobin level increase was observed (2.49 g/dl in the ferric carboxymaltose group vs. 1.56 g/dl in the placebo group, P = 0.02). At day 180, QOL, measured on European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, improved by 10.5 points in the ferric carboxymaltose group and by 8.2 points in the placebo group (P = 0.56). Rates of adverse events and rehospitalisation were similar in the two groups., Conclusions: Intravenous iron seems safe and effective to treat anaemia in older patients after AGIB and should be considered as a standard-of-care treatment. ClinicalTrials.gov (NCT01690585)., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
43. Has the time come for a systematic top-down approach in Crohn's disease?
- Author
-
Fumery M and Buisson A
- Subjects
- Humans, Infliximab, Antibodies, Monoclonal, Crohn Disease
- Abstract
Competing Interests: MF has received consulting or lecture fees from AbbVie, Amgen, Arena, Biogen, Celltrion, CTMA, Galapagos, Janssen, MSD, Pfizer, Takeda, Tillotts, MSD, Gilead, Fresenius, Celgene, Sandoz, and Ferring. AB has received consulting fees from AbbVie, Amgen, Arena, Biogen, Celltrion, CTMA, Fresenius-Kabi, Galapagos, Janssen, MSD, Nexbiome, Pfizer, Roche, Takeda, and Tillott; lecture fees from AbbVie, Amgen, Biogen, Fresenius-Kabi, Galapagos, Janssen, Mayoli-Spindler, MSD, Norgine, Pfizer, Roche, Takeda, Tillotts, and Vifor Pharma; and research grants from AbbVie, Celltrion, Janssen, Lilly, Pfizer, and Takeda.
- Published
- 2024
- Full Text
- View/download PDF
44. Switching From Intravenous to Subcutaneous Infliximab is Safe and Feasible in Patients With Inflammatory Bowel Disease Suffering From Obesity: A Post Hoc Analysis of the REMSWITCH Study.
- Author
-
Buisson A, Nachury M, Pereira B, and Fumery M
- Subjects
- Humans, Injections, Subcutaneous, Female, Adult, Male, Middle Aged, Gastrointestinal Agents administration & dosage, Gastrointestinal Agents therapeutic use, Treatment Outcome, Drug Substitution methods, Young Adult, Infliximab administration & dosage, Infliximab therapeutic use, Obesity complications, Obesity drug therapy, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases complications, Administration, Intravenous
- Abstract
The REMSWITCH study recently demonstrated that switching from intravenous (IV) to subcutaneous (SC) infliximab (IFX) is feasible and well-accepted leading to a low risk of relapse in patients with inflammatory bowel disease (IBD).
1 Because the doses of IV IFX depend on patients' weight contrary to SC IFX, whether the switch is also feasible in patients with IBD suffering from obesity remains questionable., (Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
45. Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study.
- Author
-
Vieujean S, Laharie D, Buisson A, Roblin X, Fumery M, Nancey S, Wils P, Altwegg R, Seidel L, Caron B, and Peyrin-Biroulet L
- Subjects
- Humans, Retrospective Studies, Cohort Studies, Tumor Necrosis Factor Inhibitors therapeutic use, Remission Induction, Treatment Outcome, Colitis, Ulcerative drug therapy, Colitis, Ulcerative pathology, Piperidines, Pyrimidines
- Abstract
Background: While the efficacy of tofacitinib to induce and maintain clinical and endoscopic remission is well established in ulcerative colitis (UC), little is known about its efficacy to induce histological remission., Methods: We conducted a retrospective multicentric cohort study. UC patients ≥ 16 years treated by tofacitinib in whom histological activity has been evaluated before and after induction were eligible. The primary endpoint was the histological remission at the end of induction, assessed by the Nancy index and the epithelial neutrophilic infiltrate., Results: A total of 42 patients with UC (93% previously exposed to an anti-TNF and 81% to vedolizumab) were included between July 2018 and April 2022 and were followed for a median duration of 84 weeks [IQR, 35-134]. At the end of induction period (whether prolonged or not), 19% and 24% of patients achieved histological remission, using the Nancy index and the epithelial neutrophilic infiltrate, respectively. Survival without tofacitinib discontinuation was significantly longer in patients without epithelial neutrophilic infiltrate at the end of induction (whether prolonged or not) compared with patients with epithelial neutrophilic infiltrate (p = 0.036)., Conclusion: Tofacitinib induced histological remission in one fifth to one quarter of patients with UC who have previously failed anti-TNF or/and vedolizumab after induction (whether prolonged or not)., Competing Interests: Conflict of interests S Vieujean lecture and/or consulting fees from Abbvie, Ferring, Janssen, Takeda. D Laharie counselling, boards, transports and/or fees from Abbvie, Biogaran, Biogen, Ferring, HAC-pharma, Janssen, MSD, Novartis, Pfizer, Prometheus, Roche, Takeda, Theradiag, Tillots. A Buisson received consulting fees from AbbVie, Amgen, Arena, Biogen, Celltrion Healthcare, CTMA, Galapagos, Janssen, MSD, Nexbiome, Pfizer, Roche, Takeda, and Tillotts; and lecture fees from AbbVie, Amgen, Biogen, Galapagos, Janssen, Mayoli-Spindler, MSD, Norgine, Pfizer, Roche, Takeda, Tillotts, and Vifor Pharma. X Roblin served as a speaker, a consultant, and/or an advisory board member for MSD, Pfizer, Celltrion, Janssen, Takeda, AbbVie, Amgen, Biogen, Galapagos, Roche, and Theradiag. M Fumery declares financial support from Abbvie, MSD, Ferring, Boehringer, Pfizer, Takeda, Biogen, Amgen, Gilead, Sandoz, Celgene, Galapagos, Janssen, and Tillots Pharma. S Nancey declares lecture and/or consulting fees from Abbvie, Janssen, Ferring, Takeda, Amgen, Biogen, Novartis, Celltrion, Pfizer, MEDAC, NORDIC Pharma, Maat Pharma. P Wils declares lecture and/or consulting fees from Abbvie, Ferring, Biogen, Janssen, Celltrion, Takeda. R Altwegg declares counselling, boards, transports or fees from Abbvie, Amgen, Biogen, Ferring, Janssen, MSD, Pfizer, Takeda, Tillotts. L Seidel has no conflict of interest. B Caron declares lecture and/or consulting fees from Abbvie, Amgen, Celltrion, Ferring, Janssen, Lilly, and Takeda. L Peyrin-Biroulet declares consulting fees from AbbVie, Adacyte, Alimentiv, Alma Bio Therapeutics, Amgen, Applied Molecular Transport, Arena, Biogen, BMS, Celltrion, CONNECT Biopharm, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, HAC-Pharma, IAG Image Analysis, Index Pharmaceuticals, Inotrem, Janssen, Lilly, Medac, Mopac, Morphic, MSD, Norgine, Nordic Pharma, Novartis, OM Pharma, ONO Pharma, OSE Immunotherapeutics, Pandion Therapeutics, Par'Immune, Pfizer, Prometheus, Protagonist, Roche, Sanofi, Sandoz, Takeda, Theravance, Thermo Fisher, Tigenix, Tillots, Viatris, Vifor, Ysopia, Abivax, Samsung, Ventyx, Roivant, Vectivbio., (Copyright © 2023 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
46. Tofacitinib for Patients with Anti-TNF Refractory Ulcerative Proctitis: A Multicentre Cohort Study from the GETAID.
- Author
-
Uzzan M, Nachury M, Nuzzo A, Amiot A, Caron B, Benezech A, Buisson A, Bouguen G, Le Berre C, Reenaers C, Le Cosquer G, Savoye G, Charkaoui M, Vidon M, Guillo L, Fumery M, Peyrin-Biroulet L, Kirchgesner J, and Bouhnik Y
- Subjects
- Humans, Retrospective Studies, Quality of Life, Tumor Necrosis Factor Inhibitors therapeutic use, Proctitis drug therapy, Piperidines, Pyrimidines
- Abstract
Background: Although ulcerative proctitis [UP] can dramatically impair quality of life, treatment efficacy has been poorly investigated in UP as it was historically excluded from phase 2/3 randomised controlled trials in ulcerative colitis. Our aim was to assess the effectiveness and safety of tofacitinib for the treatment of UP., Methods: We conducted a retrospective, multicentre study in 17 GETAID centres, including consecutive patients with UP treated with tofacitinib. The primary endpoint was steroid-free remission between Week 8 and Week 14, defined as a partial Mayo score of 2 [and no individual subscore above 1]. Secondary outcomes included clinical response and steroid-free remission after induction and at 1 year., Results: All the 35 enrolled patients previously received anti-tumour necrosis factor [TNF] therapy and 88.6% were exposed to at least two lines of biologics. At baseline, the median partial Mayo score was 7 (intequartile range [IQR] [5.5-7]). After induction [W8-W14], 42.9% and 60.0% of patients achieved steroid-free remission and clinical response, respectively. At 1 year, the steroid-free clinical remission and clinical response rates were 39.4% and 45.5%, respectively, and 51.2% [17/33] were still receiving tofacitinib treatment. Survival without tofacitinib withdrawal was estimated at 50.4% (95% confidence interval [CI] [35.5-71.6]) at 1 year. Only a lower partial Mayo at baseline was independently associated with remission at induction (0dds ratio [OR] = 0.56 for an increase of 1, (95% CI [0.33-0.95], p = 0.03). Five [14.3%] adverse events were reported, with one leading to treatment withdrawal [septic shock secondary to cholecystitis]., Conclusion: Tofacitinib may offer a therapeutic option for patients with refractory UP., (© The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
47. Guselkumab in Crohn's disease: the IL-23 race continues.
- Author
-
Fumery M and Buisson A
- Subjects
- Humans, Antibodies, Monoclonal, Humanized therapeutic use, Interleukin-23, Crohn Disease drug therapy
- Abstract
Competing Interests: MF declares consulting or lecture fees from AbbVie, Amgen, Arena, Biogen, Celtrion, CTMA, Galapagos, Janssen, MSD, Pfizer, Takeda, Tillotts, MSD, Gilead, Fresenius, Celgene, Sandoz, and Ferring. AB declares consulting fees from AbbVie, Amgen, Arena, Biogen, Celtrion, CTMA, Fresenius-Kabi, Galapagos, Janssen, MSD, Nexbiome, Pfizer, Roche, Takeda and Tillotts; lecture fees from AbbVie, Amgen, Biogen, Fresenius-Kabi Galapagos, Janssen, Mayoli-Spindler, MSD, Norgine, Pfizer, Roche, Takeda, Tillotts, and Vifor Pharma; and research grants from AbbVie, Celltrion, Janssen, Lilly, Pfizer, and Takeda.
- Published
- 2024
- Full Text
- View/download PDF
48. [Enteritis cystica profunda].
- Author
-
Dréau A, Barthomeuf C, Balesdent M, Fumery M, Sabbagh C, and Chatelain D
- Subjects
- Female, Humans, Middle Aged, Constriction, Pathologic, Mucins, Crohn Disease complications, Crohn Disease diagnosis, Crohn Disease pathology, Enteritis, Ileitis diagnosis, Ileitis surgery, Ileitis pathology, Cysts diagnosis
- Abstract
Enteritis cystica profunda is a rare and benign disease defined as the invagination of the intestinal epithelium into the submucosa and more profound layers of intestinal wall leading to the formation of mucin-filled cystic spaces. We reported the case of a 45-year-old female, suffering from a Crohn's disease, with a Koenig's syndrome, diarrhea, abdominal pain and weight loss. The colonoscopy and the abdominopelvic scan showed a terminal ileal stenosis, with parietal calcifications. A surgical ileocecal resection was decided. Gross examination of the ileocecal resection showed a thickening of the ileal wall, with many mucin-filled cysts measuring 1mm to 2cm, with some calcifications. The ileal mucosa was ulcerated, and showed a stenotic sector extending over 3cm. Histological examination showed acute ulcerated ileitis lesions, with chronic ileitis lesions and stenosis, compatible with the known diagnosis of Crohn's disease. There were also many cysts into the ileal wall. They were lined with a regular ileal epithelium. The cysts contained mucus, with some calcifications. Some cysts were ruptured, with extravasation of mucus within the wall. Cystica profunda can be found anywhere along the digestive tract. The physiopathology is not yet well understood, but it seems to be favored by chronic aggression of the intestinal wall. This pathology most often coexists with Crohn's disease. The main differential diagnosis is mucinous adenocarcinoma. Cystica profunda does not require any specific treatment., (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
49. Long-term effectiveness and safety of anti-TNF in pediatric-onset inflammatory bowel diseases: A population-based study.
- Author
-
Fumery M, Dupont C, Ley D, Savoye G, Bertrand V, Guillon N, Wils P, Gower-Rousseau C, Sarter H, Turck D, and Leroyer A
- Subjects
- Adolescent, Child, Female, Humans, Young Adult, Adalimumab adverse effects, Infliximab therapeutic use, Retrospective Studies, Tumor Necrosis Factor Inhibitors therapeutic use, Tumor Necrosis Factor-alpha, Colitis, Ulcerative drug therapy, Crohn Disease drug therapy, Inflammatory Bowel Diseases drug therapy
- Abstract
Background: Anti-TNF agents are the first biologic treatment option in inflammatory bowel disease (IBD). The long-term effectiveness of this strategy at the population level is poorly known, particularly in pediatric-onset IBD., Methods: All patients diagnosed with Crohn's disease (CD) or ulcerative colitis (UC) before the age of 17 between 1988 and 2011 in the EPIMAD population-based registry were followed retrospectively until 2013. Among patients treated with anti-TNF, the cumulative probabilities of anti-TNF failure defined by primary failure, loss of response (LOR) or intolerance were evaluated. Factors associated with anti-TNF failure were investigated by a Cox model., Results: Among a total of 1,007 patients with CD and 337 patients with UC, respectively 481 (48%) and 81 (24%) were treated with anti-TNF. Median age at anti-TNF initiation was 17.4 years (IQR, 15.1-20.9). Median duration of anti-TNF therapy was 20.4 months (IQR, 6.0-59.9). In CD, the probability of failure of 1st line anti-TNF at 1, 3 and 5 years was respectively 30.7%, 51.3% and 61.9% for infliximab and 25.9%, 49.3% and 57.7% for adalimumab (p = 0.740). In UC, the probability of failure of 1st line anti-TNF therapy was respectively 38.4%, 52.3% and 72.7% for infliximab and 12.5% for these 3 timepoints for adalimumab (p = 0.091). The risk of failure was maximal in the first year of treatment and LOR was the main reason for discontinuation. Female gender was associated with LOR (HR, 1.48; 95%CI 1.02-2.14) and with anti-TNF withdrawal for intolerance in CD (HR, 2.31; 95%CI 1.30-4.11) and disease duration (≥ 2 y vs. < 2 y) was associated with LOR in UC (HR, 0.37; 95%CI 0.15-0.94) in multivariate analysis. Sixty-three (13.5%) patients observed adverse events leading to termination of treatment (p = 0.57). No death, cancer or tuberculosis was observed while the patients were under anti-TNF treatment., Conclusion: In a population-based study of pediatric-onset IBD, about 60% in CD and 70% in UC experienced anti-TNF failure within 5 years. Loss of response account for around two-thirds of failure, both for CD and UC., Competing Interests: Conflict of interest MF has received lecture/consultant fees from Abbvie, Ferring, Tillots, MSD, Biogen, Amgen, Fresenius, Hospira, Sandoz, Pfizer, Celgene, Gilead, Boehringer, Galapagos, Janssen and Takeda. CD has received consultant fees from Abbvie. PW: none DL has received lecture/consultant fees from Abbvie and Sandoz. The other authors state that they have no competing interests regarding this work to disclose., (Copyright © 2023 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.